News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

3DM Inc. Launches PuraMatrix Through Partnership With BD Biosciences (BDX)

10/19/2005 5:11:55 PM

CAMBRIDGE, Mass., Oct. 26 /PRNewswire/ -- 3DM, Inc., a Cambridge-based developer of synthetic biomaterial polymers, has announced a worldwide co- branded marketing and distribution partnership with BD Biosciences - Discovery Labware. The limited-exclusive partnership supplies BD Biosciences with 3DM's award-winning PuraMatrix Synthetic Peptide Hydrogel. The product line will be marketed by BD Biosciences as BD(TM) PuraMatrix(TM) Peptide Hydrogel.

"We are very excited to launch BD(TM) PuraMatrix(TM) Peptide Hydrogel, the latest addition to our extensive product line for 3D cell culture, drug discovery, tissue engineering, and stem cell biology," said David Freeman, VP, Marketing, BD Biosciences - Discovery Labware. "It is a truly novel technology with a myriad of applications in the life sciences. We are extremely encouraged by the publication of numerous studies from distinguished research institutions that are currently using this important biomaterial."

BD Biosciences will market these products to the drug discovery and life science research communities as a novel nanobiotechnology for the culture of cells and tissues. Applications include cell-based assays, tissue engineering, cell biology research, and stem cell bioproduction.

"This partnership with BD Biosciences is a major milestone in our mission to enable broad use of PuraMatrix across multiple life science and drug discovery applications," said Zen Chu, President and co-founder of 3DM. "This relationship serves as a foundation to advance new PuraMatrix applications, including toxicology testing models, cancer biology, tissue models for drug discovery, and stem cell regenerative medicine."

About PuraMatrix

PuraMatrix Hydrogels are used to create synthetic nanofiber scaffolds to culture cells for basic research, drug discovery and bioproduction. Clinical versions of PuraMatrix are currently in animal testing for medical device applications in orthopedic implants and cardiac regeneration.

PuraMatrix provides a number of advantages over current solutions: * Synthetic and transparent yet biocompatible hydrogel composition (1% peptide [w/v] 99% water) * Cultures and supports attachment of most cell and tissue types in highly defined conditions * Supports hepatotoxicity, angiogenesis, stem cell proliferation and tumor cell motility assays * Promotes differentiation of hepatocyte progenitor cells and other cell types

BD(TM) PuraMatrix(TM) is distributed exclusively through BD Biosciences. Product information can be found at:

PuraMatrix(TM) is forward compatible with in vivo implant studies and bioproduction requirements, and is already in use at major pharmaceutical companies and clinical research institutions. Other versions of PuraMatrix are compatible with cGMP quality requirements and clinical therapeutics and are available directly from 3DM Inc.

About 3DM, Inc.

3DM is a privately-held specialty biomaterials and medical device company headquartered in Cambridge, Mass. The patented technology, exclusively licensed from Massachusetts Institute of Technology, was pioneered through the work and expertise of Drs. Shuguang Zhang, Alan Grodzinsky, Robert Langer, Alexander Rich, Carlos Semino and Lisa Spirio. Contact 3DM directly for supplying high volume and GMP-quality applications for bioproduction, medical devices and drug delivery applications at

Contact: Zen Chu, President 3DM, Inc. 877-430-9595 Media: Jennifer Gray MacDougall BioCommunications 508-647-0209

3DM, Inc.

CONTACT: Zen Chu, President of 3DM, Inc., +1-877-430-9595,; or Jennifer Gray of MacDougall BioCommunications,+1-508-647-0209

Read at

comments powered by Disqus